Search Result

Pathways Recommended:	Neuronal Signaling JAK/STAT Signaling

Results for "

cAMP/PKA signals

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PKA (16) Akt (1) AMPK (2) AP-1 (2) Apoptosis (2) Caspase (2) Collagen (1) Epigenetic Reader Domain (3) ERK (3) FASTK (2) GSK-3 (1) Interleukin Related (2) Keap1-Nrf2 (2) Kisspeptin Receptor (2) NF-κB (2) PACAP Receptor (1) Phosphodiesterase (PDE) (4) PI3K (1) PKC (2) Potassium Channel (2) Ras (3) ROCK (2) Serpin (1) Sirtuin (2) TNF Receptor (1) Toll-like Receptor (TLR) (2) TSH Receptor (1) Tyrosinase (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (2) Endocrinology (3) Inflammation/Immunology (5) Metabolic Disease (10) Neurological Disease (3)

By Targets:

PKA (16)

Akt (1)

AMPK (2)

AP-1 (2)

Apoptosis (2)

Caspase (2)

Collagen (1)

Epigenetic Reader Domain (3)

ERK (3)

FASTK (2)

GSK-3 (1)

Interleukin Related (2)

Keap1-Nrf2 (2)

Kisspeptin Receptor (2)

NF-κB (2)

PACAP Receptor (1)

Phosphodiesterase (PDE) (4)

PI3K (1)

PKC (2)

Potassium Channel (2)

Ras (3)

ROCK (2)

Serpin (1)

Sirtuin (2)

TNF Receptor (1)

Toll-like Receptor (TLR) (2)

TSH Receptor (1)

Tyrosinase (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (2)

Endocrinology (3)

Inflammation/Immunology (5)

Metabolic Disease (10)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: PKA

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P991202

Anti-TSHR Antibody (M22)	TSH Receptor PKA	Metabolic Disease Inflammation/Immunology
Anti-TSHR Antibody (M22) is a selective agonist targeting TSHR (thyroid-stimulating hormone receptor), acting through competitive binding to the extracellular domain of TSHR. Anti-TSHR Antibody (M22) can mimic the biological effects of thyroid-stimulating hormone (TSH), activating downstream *cAMP-PKA* and other signaling pathways. Anti-TSHR Antibody (M22) can stimulate the proliferation of thyroid follicular epithelial cells and human umbilical vein endothelial cells (HUVECs), promote angiogenesis and tube formation, cell migration, and also upregulate the expression of angiogenesis-related proteins such as PROX1. Anti-TSHR Antibody (M22) can be used in research areas such as the mechanisms of goiter formation in Graves' disease (GD), angiogenesis regulation, and TSHR antagonist screening .

HY-103322

6-Bnz-cAMP sodium salt	PKA Potassium Channel	Metabolic Disease Cancer
6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective *PKA* activator with inhibitory activity against the bTREK-1 K ⁺ channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K ⁺ channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration .

HY-P10927A

BRP TFA BRINP2-related peptide TFA	PKA AP-1	Metabolic Disease
BRP (BRINP2-related peptide) TFA is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP TFA induces the central activation of FOS in neuronal cells via the *cAMP-PKA-CREB* signaling pathway. BRP TFA exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP TFA is independent of the leptin, GLP-1 receptor and melanocortin 4 receptor pathways. BRP TFA is applicable to obesity-related research .

HY-P10927

BRP BRINP2-related peptide	AP-1 PKA	Metabolic Disease
BRP is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP induces the central activation of FOS in neuronal cells via the *cAMP-PKA-CREB* signaling pathway. BRP exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP is independent of the leptin, GLP-1 receptor and melanocortin 4 receptor pathways. BRP is applicable to obesity-related research .

HY-P6292

KS-133	PACAP Receptor PKA ERK PI3K Akt GSK-3	Neurological Disease Cancer
KS-133 is a bicyclic peptide with VIPR2 antagonistic activity that can cross the blood-brain barrier. KS-133 selectively blocks VIPR2-mediated Gq/Ca, Gs/cAMP, cAMP/PKA/ERK and PI3K/AKT/GSK3β signaling pathways. KS-133 inhibits VIPR2 agonist-induced CREB phosphorylation in the prefrontal cortex of mice. KS-133 shifts the polarization direction of macrophages toward M1. KS-133 attenuates cancer cell proliferation and reduces the cell cycle distribution level at the S-M phase. KS-133 exerts antitumor effects in a mouse model of colorectal cancer. KS-133 reverses cognitive decline in mouse models of psychiatric disorders. KS-133 can be used for research related to schizophrenia, colorectal cancer and breast cancer .

HY-107544

8-pCPT-2'-O-Me-cAMP-AM	PKA	Metabolic Disease
8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with *PKA* pathway .

HY-110218

CW 008 2 Publications Verification	PKA Epigenetic Reader Domain	Others
CW 008, a derivative of pyrazole-pyridine, is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion .

HY-P10336

Serpinin	Serpin	Neurological Disease Endocrinology
Serpinin is an agonist of the protease inhibitor Nexin-1 (PN-1). Serpinin upregulates the expression of PN-1 through the cAMP-PKA-Sp1 signaling pathway, promoting granule biogenesis in endocrine cells. Serpinin is used in research related to the regulation of secretory function . Serpinin is a selective agonist for β-adrenergic receptors. Serpinin interacts with β1-adrenergic receptors to activate the AC-cAMP-PKA pathway, which regulates myocardial systolic and diastolic function. pGlu-serpinin upregulates Bcl2 mRNA transcription and exerts neuroprotective effects .

HY-N12378

β-Patchoulene	NF-κB Toll-like Receptor (TLR) PKA Epigenetic Reader Domain Keap1-Nrf2 Sirtuin AMPK Caspase FASTK ERK ROCK Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
β-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. β-Patchoulene inhibits the NF-κB, TLR4, and *cAMP/PKA/CREB* signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, ROCK1/MLC2 for inhibition. β-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. β-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma .

HY-P10256A

Kiss2 peptide acetate	Kisspeptin Receptor PKA PKC	Endocrinology
Kiss2 peptide acetate is the acetate form of Kiss2 pepride (HY-P10256). Kiss2 peptide acetate is a positive regulator of reproduction. Kiss2 peptide acetate binds with its cognate receptor Kiss2R (GPR54) in COS-7 cells, activates PKA and PKC signaling pathways through Gas and Gaq proteins, and thus enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc) .

HY-134263

8-Br-cAMP-AM	PKA Ras	Cardiovascular Disease
8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury .

HY-179407

LT-104A	Phosphodiesterase (PDE)	Inflammation/Immunology
LT-104A is a potent PDE4 inhibitor that elevates intracellular cAMP levels (EC₅₀ = 1.9 μM) and inhibits PDE4D3 activity (IC₅₀ = 9.3 μM). LT-104A activates the cAMP-PKA-CREB anti-inflammatory signaling pathway and suppresses NF-κB-related gene expression (Il1b and Nos2). LT-104A can be used for inflammation-related disease research .

HY-134298

8-CPT-6-Phe-cAMP 8-(4-Chlorophenylthio)-N6-phenyl-cAMP	PKA	Others
8-CPT-6-Phe-cAMP is an analogue of signal molecule cAMP and a potent protein kinase A (PKA) activator .

HY-134340

8-pMeOPT-2'-O-Me-cAMP 8-(4-Methoxyphenylthio)-2'-O-Me-cAMP	Ras	Others
8-pMeOPT-2'-O-Me-cAMP is an analogue of the signal molecule cAMP and a potent stimulator of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP does .

HY-134264

8-Br-2'-O-Me-cAMP	Ras	Cardiovascular Disease Neurological Disease
8-Br-2'-O-Me-cAMP is an analogue of the signal molecule cyclic AMP (cAMP). 8-Br-2'-O-Me-cAMP is an agonist of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP do. 8-Br-2'-O-Me-cAMP can be used in cardiovascular disease research .

HY-137381

6-Bnz-cAMP N6-Benzoyl-cAMP	PKA Potassium Channel	Metabolic Disease
6-Bnz-cAMP, a derivative of cyclic adenosine monophosphate (cAMP), is a selective *PKA* activator with inhibitory activity against the bTREK-1 K ⁺ channel. 6-Bnz-cAMP does not activate the Epac signaling pathway. 6-Bnz-cAMP inhibits the bTREK-1 K ⁺ channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. 6-Bnz-cAMP can be used in studies related to bone tissue repair and regeneration .

HY-P10256

Kiss2 peptide	Kisspeptin Receptor PKA PKC	Endocrinology
Kiss2 peptide is a positive regulator of reproduction. Kiss2 peptide binds with its cognate receptor Kiss2R (GPR54) in COS-7 cells, activates PKA and PKC signaling pathways through Gas and Gaq proteins, and thus enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc) .

HY-157010

AP736	Tyrosinase PKA	Others
AP736 is a potent tyrosinase inhibitor (IC₅₀ = 0.9 μM) with anti-melanogenesis activity in normal human melanocytes (IC₅₀ = 0.11 μM). AP736 suppresses the expression of tyrosinase and TRP-1/2 by inhibiting the cAMP-PKA-CREB signalling axis, leading to reduced microphthalmia-associated transcription factor (MITF) transcripts and proteins. AP736 can be used for melanogenesis and hyperpigmentation research .

HY-178478

PDE1-IN-11	Phosphodiesterase (PDE)	Metabolic Disease
PDE1-IN-11 (Compound 5cc) is an orally active and highly selective PDE1A1 inhibitor. PDE1-IN-11 increases intracellular cAMP and cGMP levels, activating the PKA-CREB and NO-cGMP-PKG signaling pathways, promoting osteoblast differentiation and bone formation, while suppressing osteoclastogenesis and bone resorption. PDE1-IN-11 is promising for research of postmenopausal osteoporosis (PMO) and other bone metabolism disorders .

HY-179645

Phosphodiesterase-IN-5	Phosphodiesterase (PDE) PKA Interleukin Related TNF Receptor Collagen	Inflammation/Immunology
Phosphodiesterase-IN-5 is a potent, orally active and selective phosphodiesterase 10A (PDE10A) inhibitor with an IC₅₀ of 6.2 nM. Phosphodiesterase-IN-5 shows >1612-fold selectivity over other PDEs. Phosphodiesterase-IN-5 exhibits potent antifibrotic efficacy in a Bleomycin (BLM) (HY-108345)-induced murine model of pulmonary fibrosis (PF) by blocking myofibroblast differentiation via the cAMP/PKA/CREB signaling pathway. Phosphodiesterase-IN-5 can be used for the research of PF .

HY-N12378A

α-Patchoulene	AMPK FASTK Sirtuin ROCK Keap1-Nrf2 Toll-like Receptor (TLR) Apoptosis PKA ERK NF-κB Epigenetic Reader Domain Caspase	Metabolic Disease Inflammation/Immunology Cancer
α-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. α-Patchoulene inhibits the NF-κB, TLR4, and *cAMP/PKA/CREB* signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, ROCK1/MLC2 for inhibition. α-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. α-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma .

HY-181088

PDE3/4-IN-4	Phosphodiesterase (PDE) Interleukin Related	Metabolic Disease
PDE3/4-IN-4 is an orally active PDE3A and PDE4B inhibitor with IC₅₀ values of 10 nM and 9.4 nM, respectively. PDE3/4-IN-4 shows selective activity relative to most other PDE family members. PDE3/4-IN-4 modulates the cAMP/PKA/CREB signaling pathway. PDE3/4-IN-4 inhibits pro-inflammatory factor IL-6. PDE3/4-IN-4 reduces expression of inflammatory markers in liver tissue. PDE3/4-IN-4 attenuates liver fibrosis. PDE3/4-IN-4 limits liver damage in cholestatic and sepsis-induced liver disease mice models. PDE3/4-IN-4 can be used for the research of liver injury, cholestatic liver diseases, sepsis-induced liver injury .

Cat. No.	Product Name	Target	Research Area